Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firmonertinib and Radiotherapy in Stage III EGFR Uncommon Mutation NSCLC
NCT07314216Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Jun 2026
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Hunan Cancer Hospital. Started Jun 2026; status: recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07314216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07314216.